A practical approach to managing patients with HCV infection.

International Journal of Medical Sciences
Richard H Huang, Ke-Qin Hu

Abstract

Hepatitis C virus (HCV) infection is a major worldwide public health concern. It is a common cause of chronic liver disease and hepatocellular carcinoma. HCV antibody and HCV RNA testing are available diagnostic studies that offer high degree of accuracy. Current standard therapy includes a combination of pegylated interferon and ribavirin. Response rate is approximately 40% for genotype 1 and 80% for genotypes 2 and 3, respectively. Successful treatment can stop the progression of chronic liver disease, reduce the need for liver transplantation, and possibly decrease the risk for Hepatocellular carcinoma (HCC). Evaluating for potential treatment candidacy is an important initial step in the management of chronic HCV infection as not all individuals may need or qualify for the treatment. Understanding the natural history, the different diagnostic modalities, the current therapeutic options and, the treatment response and adverse effect profiles can help the practitioners better manage chronic HCV infection.

References

Apr 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P J ScheuerG M Dusheiko
Jul 11, 1991·The New England Journal of Medicine·P FarciR H Purcell
Mar 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M BarreraA Ordinas
Feb 3, 1998·The American Journal of Gastroenterology·S G ShethS Chopra
Apr 16, 1998·Journal of Hepatology·J P ZarskiD Dhumeaux
Sep 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T E WileyT J Layden
Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J E WareG L Davis
Aug 19, 1999·The New England Journal of Medicine·M J AlterH S Margolis
Sep 25, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y BenhamouT Poynard
Jan 22, 2000·Annals of Internal Medicine·L B SeeffE L Kaplan
Feb 15, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L B SeeffL Barbosa
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jean-Michel Pawlotsky
Dec 17, 2002·Gastroenterology Clinics of North America·Mukesh G Harisinghani, Peter F Hahn
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Apr 2, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Doris B StraderUNKNOWN American Association for the Study of Liver Diseases
Mar 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brennan M R SpiegelFasiha Kanwal

❮ Previous
Next ❯

Citations

Jan 1, 2011·Therapeutic Advances in Chronic Disease·Emilio Palumbo
Feb 23, 2013·Biochimica Et Biophysica Acta·Cheng-Yi ChenKwang-Huei Lin
Oct 13, 2009·European Journal of Internal Medicine·Abdel Halim A MoustafaHeba I Abdou
Feb 7, 2008·Liver International : Official Journal of the International Association for the Study of the Liver·Alexander TanPei-Jer Chen
May 13, 2009·American Journal of Therapeutics·Emilio Palumbo

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunoassay
ELISA
biopsy
contraception

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

© 2022 Meta ULC. All rights reserved